Prognostic and predictive biomarkers in adult and pediatric gliomas: Toward personalized treatment

Frontiers in Oncology

Volumn 4 MAR, Issue , 2014, Pages

  Haynes, Harry R ^a   Camelo Piragua, Sandra ^b   Kurian, Kathreena M ^a  

^a FRENCHAY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Gliomas; Predictive biomarkers; Prognostic biomarkers

Indexed keywords

B RAF KINASE; BEVACIZUMAB; BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ADULT; BRAIN TUMOR; CANCER PROGNOSIS; CANCER STEM CELL; CARCINOGENESIS; CELL HETEROGENEITY; CHILD; DNA SEQUENCE; GENE AMPLIFICATION; GENE MUTATION; GLIOBLASTOMA; GLIOMA; HUMAN; METHYLATION; MORBIDITY; OLIGODENDROGLIOMA; PHASE 3 CLINICAL TRIAL (TOPIC); PILOCYTIC ASTROCYTOMA; PLEOMORPHIC XANTHOASTROCYTOMA; PREDICTION; PREDICTIVE VALIDITY; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION;

EID: 84901020239     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00047     Document Type: Review

References (194)

1. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol (2005) 109:93-108. doi:10.1007/s00401-005-0991-y.
2. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO Classification of Tumours of the Central Nervous System. 4th ed. Geneva: IARC (2007).
3. Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res (2013) 19:764-72. doi:10.1158/1078-0432.CCR-12-3002.
4. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre P-L, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res (2004) 64:6892-9. doi:10.1158/0008-5472.CAN-04-1337.
5. Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol (1996) 6:217-23; discussion 23-4. doi:10.1111/j.1750-3639.1996.tb00848.x.
6. McDonald KL, Aw G, Kleihues P. Role of biomarkers in the clinical management of glioblastomas: what are the barriers and how can we overcome them? Front Neurol (2012) 3:188. doi:10.3389/fneur.2012.00188.
7. Lai A, Kharbanda S, Pope WB, Tran A, Solis OE, Peale F, et al. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol (2011) 29:4482-90. doi:10.1200/JCO.2010.33.8715.
8. Bartek J, Ng K, Fischer W, Carter B, Chen CC. Key concepts in glioblastoma therapy. J Neurol Neurosurg Psychiatry (2012) 83:753-60. doi:10.1136/jnnp-2011-300709.
9. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 455:1061-8. doi:10.1038/nature07385.a
10. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 17:98-110. doi:10.1016/j.ccr.2009.12.020.
11. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell (2006) 9:157-73. doi:10.1016/j.ccr.2006.02.019.
12. Riemenschneider MJ, Louis DN, Weller M, Hau P. Refined brain tumor diagnostics and stratified therapies: the requirement for a multi- disciplinary approach. Acta Neuropathol (2013) 126:21-37. doi:10.1007/s00401-013-1127-4.
13. Zheng S, Chheda MG, Verhaak RG. Studying a complex tumor: potential and pitfalls. Cancer J (2012) 18:107-14. doi:10.1097/PPO.0b013e3182431c57.
14. Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Curr Treat Options Oncol (2012) 13:417-36. doi:10.1007/s11864-012-0210-8.
15. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell (2013) 155:462-77. doi:10.1016/j.cell.2013.09.034.
16. Johnson DR, Galanis E. Incorporation of prognostic and predictive factors into glioma clinical trials. Curr Oncol Rep (2013) 15:56-63. doi:10.1007/s11912-012-0279-z.
17. Galanis E, Wu W, Sarkaria J, Chang SM, Colman H, Sargent D, et al. Incorporation of biomarker assessment in novel clinical trial designs: personalizing brain tumor treatments. Curr Oncol Rep (2011) 13:42-9. doi:10.1007/s11912-010-0144-x.
18. Conley BA, Taube SE. Prognostic and predictive markers in cancer. Dis Markers (2004) 20:35-43. doi:10.1155/2004/202031.
19. Kloosterhof NK, Bralten LB, Dubbink HJ, French PJ, van den Bent MJ. Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma? Lancet Oncol (2011) 12:83-91. doi:10.1016/S1470-2045(10)70053-X.
20. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 360:765-73. doi:10.1056/NEJMoa0808710.
21. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol (2008) 116:597-602. doi:10.1007/s00401-008-0455-2.
22. Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol (2009) 27:4150-4. doi:10.1200/JCO.2009.21.9832.
23. Ahmadi R, Stockhammer F, Becker N, Hohlen K, Misch M, Christians A, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas. J Neurooncol (2012) 109:15-22. doi:10.1007/s11060-012-0863-y.
24. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol (2009) 118:469-74. doi:10.1007/s00401-009-0561-9.
25. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol (2009) 174:1149-53. doi:10.2353/ajpath.2009.080958.
26. Mao H, Lebrun DG, Yang J, Zhu VF, Li M. Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets. Cancer Invest (2012) 30:48-56. doi:10.3109/07357907.2011.630050.
27. Rich JN, Hans C, Jones B, Iversen ES, McLendon RE, Rasheed BK, et al. Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res (2005) 65:4051-8. doi:10.1158/0008-5472.CAN-04-3936.
28. Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, et al. Long-term survival with glioblastoma multiforme. Brain (2007) 130:2596-606. doi:10.1093/brain/awm204.
29. Chen Y-J, Hakin-Smith V, Teo M, Xinarianos GE, Jellinek DA, Carroll T, et al. Association of mutant TP53 with alternative lengthening of telomeres and favorable prognosis in glioma. Cancer Res (2006) 66:6473-6. doi:10.1158/0008-5472.CAN-06-0910.
30. Hakin-Smith V, Jellinek DA, Levy D, Carroll T, Teo M, Timperley WR, et al. Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet (2003) 361:836-8. doi:10.1016/S0140-6736(03)12681-5.
31. Liu X-Y, Gerges N, Korshunov A, Sabha N, Khuong-Quang D-A, Fontebasso AM, et al. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol (2012) 124(5):615-25. doi:10.1007/s00401-012-1031-3.
32. Kannan K, Inagaki A, Silber J, Gorovets D, Zhang J, Kastenhuber ER, et al. Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget (2012) 3:1194-203.
33. De La Fuente R, Baumann C, Viveiros MM. Role of ATRX in chromatin structure and function: implications for chromosome instability and human disease. Reproduction (2011) 142:221-34. doi:10.1530/REP-10-0380.
34. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 110:6021-6. doi:10.1073/pnas.1303607110.
35. Arita H, Narita Y, Fukushima S, Tateishi K, Matsushita Y, Yoshida A, et al. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol (2013) 126:267-76. doi:10.1007/s00401-013-1141-6.
36. Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF, et al. Frequent ATRX, CIC, and FUBP1 mutations refine the classification of malignant gliomas. Oncotarget (2012) 3:709-22.
37. Ohgaki H, Kleihues P. Genetic profile of astrocytic and oligodendroglial gli- omas. Brain Tumor Pathol (2011) 28:177-83. doi:10.1007/s10014-011-0029-1.
38. Nonoguchi N, Ohta T, Oh J-E, Kim Y-H, Kleihues P, Ohgaki H. TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathol (2013) 126(6):931-7. doi:10.1007/s00401-013-1163-0.
39. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature (2009) 462:739-44. doi:10.1038/nature08617.
40. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature (2012) 483:474-8. doi:10.1038/nature10860.
41. Bleeker FE, Molenaar RJ, Leenstra S. Recent advances in the molecular understanding of glioblastoma. J Neurooncol (2012) 108:11-27. doi:10.1007/s11060-011-0793-0.
42. Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature (2012) 483:479-83. doi:10.1038/nature10866.
43. Venneti S, Felicella MM, Coyne T, Phillips JJ, Gorovets D, Huse JT, et al. Histone 3 lysine 9 trimethylation is differentially associated with isocitrate dehydrogenase mutations in oligodendrogliomas and high-grade astrocytomas. J Neuropathol Exp Neurol (2013) 72:298-306. doi:10.1097/NEN.0b013e3182898113.
44. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 17:510-22. doi:10.1016/j.ccr.2010.03.017.
45. Olar A, Aldape KD. Using the molecular classification of glioblastoma to inform personalized treatment. J Pathol (2014) 232:165-77. doi:10.1002/path.4282.
46. Choi C, Ganji SK, DeBerardinis RJ, Hatanpaa KJ, Rakheja D, Kovacs Z, et al. 2-Hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med (2012) 18:624-9. doi:10.1038/nm.2682.
47. Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science (2013) 340:626-30. doi:10.1126/science.1236062.
48. Malzkorn B, Wolter M, Riemenschneider MJ, Reifenberger G. Unraveling the glioma epigenome: from molecular mechanisms to novel biomarkers and therapeutic targets. Brain Pathol (2011) 21:619-32. doi:10.1111/j.1750-3639.2011.00536.x.
49. Pegg AE, Dolan ME, Moschel RC. Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol (1995) 51:167-223. doi:10.1016/S0079-6603(08)60879-X.
50. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med (2000) 343:1350-4. doi:10.1056/NEJM200011093431901.
51. Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med (2005) 352:997-1003. doi:10.1056/NEJMoa043331.
52. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol (2009) 10:459-66. doi:10.1016/S1470-2045(09)70025-7.
53. Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: a systematic review and meta-analysis. J Neurooncol (2011) 105:325-35. doi:10.1007/s11060-011-0594-5.
54. Dunn J, Baborie A, Alam F, Joyce K, Moxham M, Sibson R, et al. Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer (2009) 101:124-31. doi:10.1038/sj.bjc.6605127.
55. Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol (2012) 13:707-15. doi:10.1016/S1470-2045(12)70164-X.
56. Malmström A, Grønberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol (2012) 13:916-26. doi:10.1016/S1470-2045(12)70265-6.
57. van den Bent MJ, Erdem-Eraslan L, Idbaih A, de Rooi J, Eilers PH, Spliet WG, et al. MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic oligodendrogliomas and oligoastrocytomas. A report from EORTC study 26951. Clin Cancer Res (2013) 19:5513-22. doi:10.1158/1078-0432.CCR-13-1157.
58. Zhang Y, Dutta A, Abounader R. The role of microRNAs in glioma initiation and progression. Front Biosci (Landmark Ed) (2012) 17:700-12. doi:10.2741/3952.
59. Conti A, Aguennouz M, La Torre D, Tomasello C, Cardali S, Angileri FF, et al. miR-21 and 221 upregulation and miR-181b downregulation in human grade II-IV astrocytic tumors. J Neurooncol (2009) 93:325-32. doi:10.1007/s11060-009-9797-4.
60. Gabriely G, Wurdinger T, Kesari S, Esau CC, Burchard J, Linsley PS, et al. MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol Cell Biol (2008) 28:5369-80. doi:10.1128/MCB.00479-08.
61. Ciafrè SA, Galardi S, Mangiola A, Ferracin M, Liu C-G, Sabatino G, et al. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun (2005) 334:1351-8. doi:10.1016/j.bbrc.2005.07.030.
62. Slaby O, Lakomy R, Fadrus P, Hrstka R, Kren L, Lzicarova E, et al. MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients. Neoplasma (2010) 57:264-9. doi:10.4149/neo_2010_03_264.
63. Zhang W, Zhang J, Hoadley K, Kushwaha D, Ramakrishnan V, Li S, et al. miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression. Neuro Oncol (2012) 14:712-9. doi:10.1093/neuonc/nos089.
64. Kreth S, Limbeck E, Hinske LC, Schütz SV, Thon N, Hoefig K, et al. In human glioblastomas transcript elongation by alternative polyadenylation and miRNA targeting is a potent mechanism of MGMT silencing. Acta Neuropathol (2013) 125:671-81. doi:10.1007/s00401-013-1081-1.
65. Kim T-M, Huang W, Park R, Park PJ, Johnson MD. A developmental taxonomy of glioblastoma defined and maintained by MicroRNAs. Cancer Res (2011) 71:3387-99. doi:10.1158/0008-5472.CAN-10-4117.
66. Cairncross G, Jenkins R. Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma. Cancer J (2008) 14:352-7. doi:10.1097/PPO.0b013e31818d8178.
67. Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol (2000) 18:636-45.
68. Cairncross JG, Wang M, Jenkins RB, Shaw EG, Giannini C, Brachman DG, et al. Chemotherapy plus radiotherapy (CT-RT) versus RT alone for patients with anaplastic oligodendroglioma: long-term results of the RTOG 9402 phase III study. J Clin Oncol (2012) 30:2008b.
69. van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre J-Y, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol (2012) 31(3):344-50. doi:10.1200/JCO.2012.43.2229.
70. Bettegowda C, Agrawal N, Jiao Y, Sausen M, Wood LD, Hruban RH, et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science (2011) 333:1453-5. doi:10.1126/science.1210557.
71. Yip S, Butterfield YS, Morozova O, Chittaranjan S, Blough MD, An J, et al. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol (2012) 226:7-16. doi:10.1002/path.2995.
72. Hsiao H-H, Nath A, Lin C-Y, Folta-Stogniew EJ, Rhoades E, Braddock DT. Quantitative characterization of the interactions among c-myc transcriptional regulators FUSE, FBP, and FIR. Biochemistry (2010) 49:4620-34. doi:10.1021/bi9021445.
73. Roch F, Jiménez G, Casanova J. EGFR signalling inhibits capicua-dependent repression during specification of Drosophila wing veins. Development (2002) 129:993-1002.
74. Nakamura M, Yang F, Fujisawa H, Yonekawa Y, Kleihues P, Ohgaki H. Loss of heterozygosity on chromosome 19 in secondary glioblastomas. J Neuropathol Exp Neurol (2000) 59:539-43.
75. Homma T, Fukushima T, Vaccarella S, Yonekawa Y, Di Patre PL, Franceschi S, et al. Correlation among pathology, genotype, and patient outcomes in glioblastoma. J Neuropathol Exp Neurol (2006) 65:846-54. doi:10.1097/01.jnen.0000235118.75182.94.
76. Ichimura K, Vogazianou AP, Liu L, Pearson DM, Bäcklund LM, Plant K, et al. 1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas. Oncogene (2008) 27:2097-108. doi:10.1038/sj.onc.1210848.
77. Burton EC, Lamborn KR, Feuerstein BG, Prados M, Scott J, Forsyth P, et al. Genetic aberrations defined by comparative genomic hybridization distinguish long-term from typical survivors of glioblastoma. Cancer Res (2002) 62:6205-10.
78. Solomon DA, Kim J-S, Jean W, Waldman T. Conspirators in a capital crime: co-deletion of p18INK4c and p16INK4a/p14ARF/p15INK4b in glioblastoma multiforme. Cancer Res (2008) 68:8657-60. doi:10.1158/0008-5472.CAN-08-2084.
79. Rao SK, Edwards J, Joshi AD, Siu I-M, Riggins GJ. A survey of glioblastoma genomic amplifications and deletions. J Neurooncol (2010) 96:169-79. doi:10.1007/s11060-009-9959-4.
80. Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J, et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol (2009) 27:5743-50. doi:10.1200/JCO.2009.23.0805.
81. Kim J-H, Huse JT, Huang Y, Lyden D, Greenfield JP. Molecular diagnostics in paediatric glial tumours. Lancet Oncol (2013) 14:e19-27. doi:10.1016/S1470-2045(12)70577-6.
82. Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, Castano A, et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science (2012) 337:1231-5. doi:10.1126/science.1220834.
83. Gavine PR, Mooney L, Kilgour E, Thomas AP, Al-Kadhimi K, Beck S, et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res (2012) 72:2045-56. doi:10.1158/0008-5472.CAN-11-3034.
84. Guagnano V, Kauffmann A, Wöhrle S, Stamm C, Ito M, Barys L, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov (2012) 2:1118-33. doi:10.1158/2159-8290.CD-12-0210.
85. Hegi ME, Rajakannu P, Weller M. Epidermal growth factor receptor: a re-emerging target in glioblastoma. Curr Opin Neurol (2012) 25:774-9. doi:10.1097/WCO.0b013e328359b0bc.
86. Patel R, Leung HY. Targeting the EGFR-family for therapy: biological challenges and clinical perspective. Curr Pharm Des (2012) 18:2672-9. doi:10.2174/138161212800626148.
87. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene (2000) 19:6550-65. doi:10.1038/sj.onc.1204082.
88. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science (2007) 318:287-90. doi:10.1126/science.1142946.
89. Taylor TE, Furnari FB, Cavenee WK. Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance. Curr Cancer Drug Targets (2012) 12:197-209. doi:10.2174/156800912799277557.
90. Lassman AB, Rossi MR, Raizer JJ, Razier JR, Abrey LE, Lieberman FS, et al. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res (2005) 11:7841-50. doi:10.1158/1078-0432.CCR-05-0421.
91. Mawrin C, Diete S, Treuheit T, Kropf S, Vorwerk CK, Boltze C, et al. Prognostic relevance of MAPK expression in glioblastoma multiforme. Int J Oncol (2003) 23:641-8.
92. Koul D. PTEN signaling pathways in glioblastoma. Cancer Biol Ther (2008) 7:1321-5. doi:10.4161/cbt.7.9.6954.
93. Vivanco I, Rohle D, Versele M, Iwanami A, Kuga D, Oldrini B, et al. The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proc Natl Acad Sci U S A (2010) 107:6459-64. doi:10.1073/pnas.0911188107.
94. Wang MY, Lu KV, Zhu S, Dia EQ, Vivanco I, Shackleford GM, et al. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res (2006) 66:7864-9. doi:10.1158/0008-5472.CAN-04-4392.
95. Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, et al. Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med (2008) 5:e8. doi:10.1371/journal.pmed.0050008.
96. Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol (2005) 23:5294-304. doi:10.1200/JCO.2005.23.622.
97. Haas-Kogan DA, Prados MD, Tihan T, Eberhard DA, Jelluma N, Arvold ND, et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst (2005) 97:880-7. doi:10.1093/jnci/dji161.
98. van den Bent MJ, Brandes AA, Rampling R, Kouwenhoven MC, Kros JM, Carpentier AF, et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol (2009) 27:1268-74. doi:10.1200/JCO.2008.17.5984.
99. Available from: http://clinicaltrials.gov/show/NCT01339052.
100. Gallia GL, Rand V, Siu I-M, Eberhart CG, James CD, Marie SK, et al. PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol Cancer Res (2006) 4:709-14. doi:10.1158/1541-7786.MCR-06-0172.
101. Fan Q-W, Cheng CK, Nicolaides TP, Hackett CS, Knight ZA, Shokat KM, et al. A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res (2007) 67:7960-5. doi:10.1158/0008-5472.CAN-07-2154.
102. Fan Q-W, Weiss WA. Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance. Curr Top Microbiol Immunol (2010) 347:279-96. doi:10.1007/82_2010_67.
103. Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, Nakamura H, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res (2003) 63:6962-70.
104. Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst (2001) 93:1246-56. doi:10.1093/jnci/93.16.1246.
105. Hobbs J, Nikiforova MN, Fardo DW, Bortoluzzi S, Cieply K, Hamilton RL, et al. Paradoxical relationship between the degree of EGFR amplification and outcome in glioblastomas. Am J Surg Pathol (2012) 36:1186-93. doi:10.1097/PAS.0b013e3182518e12.
106. Pelloski CE, Lin E, Zhang L, Yung WK, Colman H, Liu J-L, et al. Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res (2006) 12:3935-41. doi:10.1158/1078-0432.CCR-05-2202.
107. Ekstrand AJ, Longo N, Hamid ML, Olson JJ, Liu L, Collins VP, et al. Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene (1994) 9:2313-20.
108. Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, et al. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res (2005) 11:1462-6. doi:10.1158/1078-0432.CCR-04-1737.
109. Huang PH, Cavenee WK, Furnari FB, White FM. Uncovering therapeutic targets for glioblastoma: a systems biology approach. Cell Cycle (2007) 6:2750-4. doi:10.4161/cc.6.22.4922.
110. Tanaka K, Babic I, Nathanson D, Akhavan D, Guo D, Gini B, et al. Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. Cancer Discov (2011) 1:524-38. doi:10.1158/2159-8290.CD-11-0124.
111. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med (2005) 353:2012-24. doi:10.1056/NEJMoa051918.
112. Lal B, Goodwin CR, Sang Y, Foss CA, Cornet K, Muzamil S, et al. EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts. Mol Cancer Ther (2009) 8:1751-60. doi:10.1158/1535-7163.MCT-09-0188.
113. Heimberger AB, Sampson JH. The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. Expert Opin Biol Ther (2009) 9:1087-98. doi:10.1517/14712590903124346.
114. Frattini V, Trifonov V, Chan JM, Castano A, Lia M, Abate F, et al. The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet (2013) 45:1141-9. doi:10.1038/ng.2734.
115. Ozawa T, Brennan CW, Wang L, Squatrito M, Sasayama T, Nakada M, et al. PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. Genes Dev (2010) 24:2205-18. doi:10.1101/gad.1972310.
116. Szerlip NJ, Pedraza A, Chakravarty D, Azim M, McGuire J, Fang Y, et al. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci U S A (2012) 109:3041-6. doi:10.1073/pnas.1114033109.
117. Phillips JJ, Aranda D, Ellison DW, Judkins AR, Croul SE, Brat DJ, et al. PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma. Brain Pathol (2013) 23(5):565-73. doi:10.1111/bpa.12043.
118. Alentorn A, Marie Y, Carpentier C, Boisselier B, Giry M, Labussière M, et al. Prevalence, clinico-pathological value, and co-occurrence of PDGFRA abnormalities in diffuse gliomas. Neuro Oncol (2012) 14:1393-403. doi:10.1093/neuonc/nos217.
119. Tanaka S, Louis DN, Curry WT, Batchelor TT, Dietrich J. Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? Nat Rev Clin Oncol (2013) 10:14-26. doi:10.1038/nrclinonc.2012.204.
120. Knizetova P, Ehrmann J, Hlobilkova A, Vancova I, Kalita O, Kolar Z, et al. Autocrine regulation of glioblastoma cell cycle progression, viability and radioresistance through the VEGF-VEGFR2 (KDR) interplay. Cell Cycle (2008) 7:2553-61. doi:10.4161/cc.7.16.6442.
121. Oehring RD, Miletic M, Valter MM, Pietsch T, Neumann J, Fimmers R, et al. Vascular endothelial growth factor (VEGF) in astrocytic gliomas-a prognostic factor? J Neurooncol (1999) 45:117-25. doi:10.1023/A:1006333005563.
122. Kuczynski EA, Patten SG, Coomber BL. VEGFR2 expression and TGF-β signaling in initial and recurrent high-grade human glioma. Oncology (2011) 81:126-34. doi:10.1159/000332849.
123. Specenier P. Bevacizumab in glioblastoma multiforme. Expert Rev Anticancer Ther (2012) 12:9-18. doi:10.1586/era.11.179.
124. Chinot OL, de La Motte Rouge T, Moore N, Zeaiter A, Das A, Phillips H, et al. AVAglio: phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv Ther (2011) 28:334-40. doi:10.1007/s12325-011-0007-3.
125. Gilbert MR, Dignam J, Won M, Blumenthal DT, Vogelbaum MA, Aldape KD, et al. RTOG 0825: phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). J Clin Oncol (2013) 31:2013.
126. Wick W, Cloughesy TF, Nishikawa R, Mason W, Saran F, Henriksson R, et al. Tumor response based on adapted Macdonald criteria and assessment of pseudoprogression (PsPD) in the phase III AVAglio trial of bevacizumab (Bv) plus temozolomide (T) plus radiotherapy (RT) in newly diagnosed glioblastoma (GBM). J Clin Oncol (2013) 4:11.
127. Weller M, Yung WK. Angiogenesis inhibition for glioblastoma at the edge: beyond AVAGlio and RTOG 0825. Neuro Oncol (2013) 15:971. doi:10.1093/neuonc/not106.
128. Rahmathulla G, Hovey EJ, Hashemi-Sadraei N, Ahluwalia MS. Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges. Onco Targets Ther (2013) 6:371-89. doi:10.2147/OTT.S38628.
129. US National Library of Medicine. Clinicaltrials.gov (2012). Available from: http://www.clinicaltrials.gov/ct2/show/NCT00329719?term=nct00329719&rank=1.
130. US National Library of Medicine. Clinicaltrails.gov (2012). Available from: http://www.clinicaltrials.gov/ct2/show/NCT00734526?term=nct00734526&rank=1.
131. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov (2006) 5:835-44. doi:10.1038/nrd2130.
132. Lee EQ, Kuhn J, Lamborn KR, Abrey L, DeAngelis LM, Lieberman F, et al. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. Neuro Oncol (2012) 14:1511-8. doi:10.1093/neuonc/nos264.
133. Neyns B, Sadones J, Chaskis C, Dujardin M, Everaert H, Lv S, et al. Phase II study of sunitinib malate in patients with recurrent high-grade glioma. J Neurooncol (2011) 103:491-501. doi:10.1007/s11060-010-0402-7.
134. Pan E, Yu D, Yue B, Potthast L, Chowdhary S, Smith P, et al. A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma. J Neurooncol (2012) 110:111-8. doi:10.1007/s11060-012-0943-z.
135. Kreisl TN, Smith P, Sul J, Salgado C, Iwamoto FM, Shih JH, et al. Continuous daily sunitinib for recurrent glioblastoma. J Neurooncol (2013) 111:41-8. doi:10.1007/s11060-012-0988-z.
136. Fontebasso AM, Liu X-Y, Sturm D, Jabado N. Chromatin remodeling defects in pediatric and young adult glioblastoma: a tale of a variant histone 3 tail. Brain Pathol (2013) 23:210-6. doi:10.1111/bpa.12023.
137. Pollack IF, Finkelstein SD, Woods J, Burnham J, Holmes EJ, Hamilton RL, et al. Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med (2002) 346:420-7. doi:10.1056/NEJMoa012224.
138. Pollack IF, Hamilton RL, Burger PC, Brat DJ, Rosenblum MK, Murdoch GH, et al. Akt activation is a common event in pediatric malignant gliomas and a potential adverse prognostic marker: a report from the Children's Oncology Group. J Neurooncol (2010) 99:155-63. doi:10.1007/s11060-010-0297-3.
139. Pollack IF, Hamilton RL, James CD, Finkelstein SD, Burnham J, Yates AJ, et al. Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort. J Neurosurg (2006) 105:418-24.
140. Pollack IF, Hamilton RL, Sobol RW, Nikiforova MN, Lyons-Weiler MA, LaFramboise WA, et al. IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children's Oncology Group. Childs Nerv Syst (2011) 27:87-94. doi:10.1007/s00381-010-1264-1.
141. Wu G, Broniscer A, McEachron TA, Lu C, Paugh BS, Becksfort J, et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet (2012) 44:251-3. doi:10.1038/ng.1102.
142. Schwartzentruber J, Korshunov A, Liu X-Y, Jones DT, Pfaff E, Jacob K, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature (2012) 482:226-31. doi:10.1038/nature10833.
143. Bosch A, Suau P. Changes in core histone variant composition in differentiating neurons: the roles of differential turnover and synthesis rates. Eur J Cell Biol (1995) 68:220-5.
144. Sturm D, Witt H, Hovestadt V, Khuong-Quang D-A, Jones DT, Konermann C, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell (2012) 22:425-37. doi:10.1016/j.ccr.2012.08.024.
145. Khuong-Quang D-A, Buczkowicz P, Rakopoulos P, Liu X-Y, Fontebasso AM, Bouffet E, et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol (2012) 124:439-47. doi:10.1007/s00401-012-0998-0.
146. Fontebasso AM, Schwartzentruber J, Khuong-Quang D-A, Liu X-Y, Sturm D, Korshunov A, et al. Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. Acta Neuropathol (2013) 125:659-69. doi:10.1007/s00401-013-1095-8.
147. Simon JA, Kingston RE. Mechanisms of polycomb gene silencing: knowns and unknowns. Nat Rev Mol Cell Biol (2009) 10:697-708. doi:10.1038/nrm2763.
148. Zhou VW, Goren A, Bernstein BE. Charting histone modifications and the functional organization of mammalian genomes. Nat Rev Genet (2011) 12:7-18. doi:10.1038/nrg2905.
149. Rheinbay E, Louis DN, Bernstein BE, Suvà ML. A tell-tail sign of chromatin: histone mutations drive pediatric glioblastoma. Cancer Cell (2012) 21:329-31. doi:10.1016/j.ccr.2012.03.001.
150. Pfister S, Witt O. Pediatric gliomas. Recent Results Cancer Res (2009) 171:67-81. doi:10.1007/978-3-540-31206-2_4.
151. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol (2005) 64:479-89.
152. Armstrong GT, Conklin HM, Huang S, Srivastava D, Sanford R, Ellison DW, et al. Survival and long-term health and cognitive outcomes after low-grade glioma. Neuro Oncol (2011) 13:223-34. doi:10.1093/neuonc/noq178.
153. Jones DT, Kocialkowski S, Liu L, Pearson DM, Bäcklund LM, Ichimura K, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res (2008) 68:8673-7. doi:10.1158/0008-5472.CAN-08-2097.
154. Jones DT, Gronych J, Lichter P, Witt O, Pfister SM. MAPK pathway activation in pilocytic astrocytoma. Cell Mol Life Sci (2012) 69:1799-811. doi:10.1007/s00018-011-0898-9.
155. Lawson AR, Hindley GF, Forshew T, Tatevossian RG, Jamie GA, Kelly GP, et al. RAF gene fusion breakpoints in pediatric brain tumors are characterized by significant enrichment of sequence microhomology. Genome Res (2011) 21:505-14. doi:10.1101/gr.115782.110.
156. Hawkins C, Walker E, Mohamed N, Zhang C, Jacob K, Shirinian M, et al. BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. Clin Cancer Res (2011) 17:4790-8. doi:10.1158/1078-0432.CCR-11-0034.
157. Lin A, Rodriguez FJ, Karajannis MA, Williams SC, Legault G, Zagzag D, et al. BRAF alterations in primary glial and glioneuronal neoplasms of the central nervous system with identification of 2 novel KIAA1549:BRAF fusion variants. J Neuropathol Exp Neurol (2012) 71:66-72. doi:10.1097/NEN.0b013e31823f2cb0.
158. Badiali M, Gleize V, Paris S, Moi L, Elhouadani S, Arcella A, et al. KIAA1549-BRAF fusions and IDH mutations can coexist in diffuse gliomas of adults. Brain Pathol (2012) 22(6):841-7. doi:10.1111/j.1750-3639.2012.00603.x.
159. Jones DT, Hutter B, Jäger N, Korshunov A, Kool M, Warnatz H-J, et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet (2013) 45:927-32. doi:10.1038/ng.2682.
160. Sievert AJ, Lang S-S, Boucher KL, Madsen PJ, Slaunwhite E, Choudhari N, et al. Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Proc Natl Acad Sci U S A (2013) 110:5957-62. doi:10.1073/pnas.1219232110.
161. Dieci MV, Arnedos M, Andre F, Soria JC. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov (2013) 3:264-79. doi:10.1158/2159-8290.CD-12-0362.
162. Rusconi P, Caiola E, Broggini M. RAS/RAF/MEK inhibitors in oncology. Curr Med Chem (2012) 19:1164-76. doi:10.2174/092986712799320510.
163. Jacob K, Albrecht S, Sollier C, Faury D, Sader E, Montpetit A, et al. Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours. Br J Cancer (2009) 101:722-33. doi:10.1038/sj.bjc.6605179.
164. Hasselblatt M, Riesmeier B, Lechtape B, Brentrup A, Stummer W, Albert FK, et al. BRAF-KIAA1549 fusion transcripts are less frequent in pilocytic astrocytomas diagnosed in adults. Neuropathol Appl Neurobiol (2011) 37:803-6. doi:10.1111/j.1365-2990.2011.01193.x.
165. Horbinski C, Nikiforova MN, Hagenkord JM, Hamilton RL, Pollack IF. Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas. Neuro Oncol (2012) 14:777-89. doi:10.1093/neuonc/nos077.
166. Nicolaides TP, Li H, Solomon DA, Hariono S, Hashizume R, Barkovich K, et al. Targeted therapy for BRAFV600E malignant astrocytoma. Clin Cancer Res (2011) 17:7595-604. doi:10.1158/1078-0432.CCR-11-1456.
167. Horbinski C. To BRAF or not to BRAF: is that even a question anymore? J Neuropathol Exp Neurol (2013) 72:2-7. doi:10.1097/NEN.0b013e318279f3db.
168. Dias-Santagata D, Lam Q, Vernovsky K, Vena N, Lennerz JK, Borger DR, et al. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One (2011) 6:e17948. doi:10.1371/journal.pone.0017948.
169. Capper D, Preusser M, Habel A, Sahm F, Ackermann U, Schindler G, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol (2011) 122:11-9. doi:10.1007/s00401-011-0841-z.
170. Chamberlain MC. Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series. J Neurooncol (2013) 114:237-40. doi:10.1007/s11060-013-1176-5.
171. Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol (2011) 121:397-405. doi:10.1007/s00401-011-0802-6.
172. Koelsche C, Wöhrer A, Jeibmann A, Schittenhelm J, Schindler G, Preusser M, et al. Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells. Acta Neuropathol (2013) 125:891-900. doi:10.1007/s00401-013-1100-2.
173. Dahiya S, Haydon DH, Alvarado D, Gurnett CA, Gutmann DH, Leonard JR. BRAF(V600E) mutation is a negative prognosticator in pediatric ganglioglioma. Acta Neuropathol (2013) 125:901-10. doi:10.1007/s00401-013-1120-y.
174. Prabowo AS, Iyer AM, Veersema TJ, Anink JJ, Schouten-van Meeteren AY, Spliet WG, et al. BRAF V600E mutation is associated with mTOR signaling activation in glioneuronal tumors. Brain Pathol (2014) 24:52-66. doi:10.1111/bpa.12081.
175. Delic S, Lottmann N, Jetschke K, Reifenberger G, Riemenschneider MJ. Identification and functional validation of CDH11, PCSK6 and SH3GL3 as novel glioma invasion-associated candidate genes. Neuropathol Appl Neurobiol (2012) 38:201-12. doi:10.1111/j.1365-2990.2011.01207.x.
176. Snuderl M, Fazlollahi L, Le LP, Nitta M, Zhelyazkova BH, Davidson CJ, et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell (2011) 20:810-7. doi:10.1016/j.ccr.2011.11.005.
177. Gillies RJ, Verduzco D, Gatenby RA. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat Rev Cancer (2012) 12:487-93. doi:10.1038/nrc3298.
178. Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer (2012) 12:323-34. doi:10.1038/nrc3261.
179. Sottoriva A, Spiteri I, Piccirillo SG, Touloumis A, Collins VP, Marioni JC, et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A (2013) 110:4009-14. doi:10.1073/pnas.1219747110.
180. Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta (2010) 1805:105-17. doi:10.1016/j.bbcan.2009.11.002.
181. Kurian KM. The impact of neural stem cell biology on CNS carcinogenesis and tumor types. Patholog Res Int (2011) 2011:685271. doi:10.4061/2011/685271.
182. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res (2004) 64:7011-21. doi:10.1158/0008-5472.CAN-04-1364.
183. Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, Bronner-Fraser M, et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A (2003) 100:15178-83. doi:10.1073/pnas.2036535100.
184. Piccirillo SG, Reynolds BA, Zanetti N, Lamorte G, Binda E, Broggi G, et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature (2006) 444:761-5. doi:10.1038/nature05349.
185. Nakano I, Saigusa K, Kornblum HI. BMPing off glioma stem cells. Cancer Cell (2008) 13:3-4. doi:10.1016/j.ccr.2007.12.018.
186. Stricker SH, Feber A, Engström PG, Carén H, Kurian KM, Takashima Y, et al. Widespread resetting of DNA methylation in glioblastoma-initiating cells suppresses malignant cellular behavior in a lineage-dependent manner. Genes Dev (2013) 27:654-69. doi:10.1101/gad.212662.112.
187. Yin C, Lv S, Chen X, Guo H. The role of glioma stem cells in glioma tumorigenesis. Front Biosci (Landmark Ed) (2014) 19:818-24. doi:10.2741/4249.
188. Cruceru ML, Neagu M, Demoulin J-B, Constantinescu SN. Therapy targets in glioblastoma and cancer stem cells: lessons from haematopoietic neoplasms. J Cell Mol Med (2013) 17:1218-35. doi:10.1111/jcmm.12122.
189. Louis DN. The next step in brain tumor classification: "let us now praise famous men" or molecules? Acta Neuropathol (2012) 124:761-2. doi:10.1007/s00401-012-1067-4.
190. Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol (2008) 26:2192-7. doi:10.1200/JCO.2007.14.8163.
191. Lalezari S, Chou AP, Tran A, Solis OE, Khanlou N, Chen W, et al. Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. Neuro Oncol (2013) 15:370-81. doi:10.1093/neuonc/nos308.
192. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol (1994) 145:1175-90.
193. Aldape K, Burger PC, Perry A. Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. Arch Pathol Lab Med (2007) 131:242-51.
194. Kuan CT, Wikstrand CJ, Bigner DD. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer (2001) 8:83-96. doi:10.1677/erc.0.0080083.